
When and How to Refer Patients for Cellular Therapy
Cellular therapy for advanced melanoma is delivered at authorized treatment centers, which makes timely referral from community oncologists essential.
Cellular therapy for advanced melanoma is delivered at authorized treatment centers, which makes timely referral from community oncologists essential. In this segment, the panel urges clinicians to refer patients early, because preparing a patient and manufacturing a product both take considerable time. The faculty address common reasons referrals are delayed. Brain metastases were excluded from the pivotal tumor-infiltrating lymphocyte (TIL) trial, but they are not an absolute barrier in standard practice. Patients can proceed once neurosurgery and radiation oncology have stabilized intracranial disease. Similarly, a history of immune-related adverse events such as colitis does not preclude referral, provided the patient has adequate cardiopulmonary reserve, and workup can begin while the toxicity is being resolved. The discussion then looks ahead to cellular therapy earlier in the treatment course. The panel reviews a global late-phase trial comparing pembrolizumab with or without lifileucel in the frontline setting, with crossover to lifileucel at progression, and explains why earlier treatment may benefit fitter patients with lower disease burden.
Related to this article








